Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers.

Date publication

janvier 2019

Journal

European urology oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr LADOIRE Sylvain

Tous les auteurs :
Martinez Chanza N, Werner L, Plimack E, Yu EY, Alva AS, Crabb SJ, Powles T, Rosenberg JE, Baniel J, Vaishampayan UN, Berthold DR, Ladoire S, Hussain SA, Milowsky MI, Agarwal N, Necchi A, Pal SK, Sternberg CN, Bellmunt J, Galsky MD, Harshman LC,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31411990

Résumé

Patients with residual muscle-invasive urinary tract cancer after neoadjuvant chemotherapy (NAC) have a high risk of recurrence.

Mots clés

Adjuvant chemotherapy, Muscle-invasive bladder cancer, Muscle-invasive urinary tract cancer, Neoadjuvant chemotherapy, Residual disease, Risk of relapse, Time to recurrence

Référence

Eur Urol Oncol. 2019 Jan 30;: